Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement

PHASE4RecruitingINTERVENTIONAL
Enrollment

1,300

Participants

Timeline

Start Date

February 21, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
AORTIC VALVE DISEASESThromboembolism
Interventions
DRUG

Rivaroxaban Oral Tablet

For 12months, Rivaroxaban oral tablet 20mg once daily For renal disorder subjects\_creatinine clearance 15-49 mL/min, 15mg once daily

DRUG

Vitamin K antagonist(warfarin)

For 12months, keep the international normalized ratio (INR) 1.7-3.0

Trial Locations (11)

Unknown

RECRUITING

Buchen Sejong Hospital, Bucheon-si

RECRUITING

Dong-A University Hospital, Busan

RECRUITING

Keimyung University Dongsan Hospital, Daegu

RECRUITING

GangNeung Asan Hospital, Gangneung

RECRUITING

Chonnam National University Hospital, Gwangju

RECRUITING

Korea University Anam Hospital, Seoul

RECRUITING

Samsung Medical Center, Seoul

RECRUITING

Seoul National University Hospital, Seoul

NOT_YET_RECRUITING

Ulsan University Hospital, Ulsan

RECRUITING

Pusan National University Yangsan Hospital, Yangsan

138-736

RECRUITING

Asan Medical Center, Seoul

All Listed Sponsors
lead

Joon Bum Kim

OTHER